AI assistant
Sending…
PFIZER INC — Major Shareholding Notification 2004
Feb 12, 2004
29831_mrq_2004-02-12_8e7b12e1-a728-4c6e-9c40-b2a5c8eb35a8.zip
Major Shareholding Notification
Open in viewerOpens in your device viewer
{# SEO P0-1: filing HTML is rendered server-side so Googlebot
sees the full text without executing JS or following an
iframe to a Disallow'd CDN path. The content has already
been sanitized through filings.seo.sanitize_filing_html. #}
SC 13G 1 bio021204.htm SCH. 13G AMENDMENT NO. 1 - BIACORE INTERNATIONAL AB OMB APPROVAL
| OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. . . 11 |
|---|
| UNITED STATES |
| SECURITIES AND EXCHANGE COMMISSION |
| Washington, D.C. 20549 |
| SCHEDULE 13G |
| Under the Securities Exchange Act of 1934 |
| (Amendment No. 1)* |
| BIACORE INTERNATIONAL AB |
| (Name of Issuer) |
| Ordinary Shares, nominal value SEK 10 each |
| (Title of Class of Securities) |
| 088658 10 9 (ADS) |
| (CUSIP Number) |
| April 16, 2003 |
| (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
| o Rule 13d-1(b) |
| o Rule 13d-1(c) |
| o Rule 13d-1(d) |
| *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
| The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
| CUSIP No. 088658 10 9 | |
|---|---|
| 1. Names of Reporting Persons. | |
| I.R.S. Identification Nos. of above persons (entities only). | |
| Pfizer Health AB (formerly called Pharmacia & Upjohn AB) | |
| 2. Check the Appropriate Box if a Member of a Group (See Instructions) | |
| (a) | |
| (b) | |
| 3. SEC Use Only | |
| 4. Citizenship or Place of Organization Sweden | |
| Number of Shares Bene-ficially Owned by Each Reporting Person With: | 5. Sole Voting Power 4,000,000 |
| 6. Shared Voting Power | |
| 7. Sole Dispositive Power 4,000,000 | |
| 8. Shared Dispositive Power | |
| 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,000,000 | |
| 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | |
| 11. Percent of Class Represented by Amount in Row (9) 41% | |
| 12. Type of Reporting Person (See Instructions) | |
| CO |
| OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. . . 11 | |
|---|---|
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| SCHEDULE 13G | |
| Under the Securities Exchange Act of 1934 | |
| (Amendment No. 1)* | |
| BIACORE INTERNATIONAL AB | |
| (Name of Issuer) | |
| Ordinary Shares, nominal value SEK 10 each | |
| (Title of Class of Securities) | |
| 088658 10 9 (ADS) | |
| (CUSIP Number) | |
| April 16, 2003 | |
| (Date of Event Which Requires Filing of this Statement) | |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: | |
| o Rule 13d-1(b) | |
| o Rule 13d-1(c) | |
| o Rule 13d-1(d) | |
| *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. | |
| The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). | |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | |
| CUSIP No. 088658 10 9 | |
| 1. Names of Reporting Persons. | |
| I.R.S. Identification Nos. of above persons (entities only). | |
| Pfizer Inc.; 13-5315170 | |
| 2. Check the Appropriate Box if a Member of a Group (See Instructions) | |
| (a) | |
| (b) | |
| 3. SEC Use Only | |
| 4. Citizenship or Place of Organization Sweden | |
| Number of Shares Bene-ficially Owned by Each Reporting Person With: | 5. Sole Voting Power 4,000,000 |
| 6. Shared Voting Power | |
| 7. Sole Dispositive Power 4,000,000 | |
| 8. Shared Dispositive Power | |
| 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,000,000 | |
| 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | |
| 11. Percent of Class Represented by Amount in Row (9) 41% | |
| 12. Type of Reporting Person (See Instructions) | |
| CO |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| February 12, 2004 |
|---|
| Date |
| /s/ Inger Brattne |
| Signature |
| Inger Brattne, Director |
| Name/Title |
More from PFIZER INC
Registration Form
2026
May 5
Interim / Quarterly Report
2026
May 5
Regulatory Filings
2026
May 5
Regulatory Filings
2026
Apr 27
Director's Dealing
2026
Mar 31
Director's Dealing
2026
Mar 31
Director's Dealing
2026
Mar 31
Director's Dealing
2026
Mar 31
Director's Dealing
2026
Mar 31
Director's Dealing
2026
Mar 31